Riociguat (Adempas, BAY 63-2521)

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
30
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Clinical Pharmacology

Conditions

Clinical Pharmacology

Trial Timeline

Feb 19, 2010 โ†’ Sep 20, 2011

About Riociguat (Adempas, BAY 63-2521)

Riociguat (Adempas, BAY 63-2521) is a phase 1 stage product being developed by Bayer for Clinical Pharmacology. The current trial status is completed. This product is registered under clinical trial identifier NCT04364464. Target conditions include Clinical Pharmacology.

Hype Score Breakdown

Clinical
10
Activity
5
Company
7
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT04366622Phase 1Completed
NCT04364464Phase 1Completed

Competing Products

20 competing products in Clinical Pharmacology

See all competitors